HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

10 Oct 2022 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

07 Sep 2022 17:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

23 Aug 2022 03:30:00 By Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

09 Aug 2022 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

08 Aug 2022 05:01:59 By Nasdaq GlobeNewswire

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

07 Aug 2022 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

15 Jul 2022 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

12 Jul 2022 19:00:00 By Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

05 Jul 2022 23:40:34 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Half-Year Financial Results

27 Jun 2022 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

01 Jun 2022 03:33:07 By Nasdaq GlobeNewswire

Appointment of Non–Executive Director

16 May 2022 06:00:02 By Nasdaq GlobeNewswire

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

02 May 2022 05:00:00 By Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

30 Mar 2022 23:00:00 By Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

11 Mar 2022 03:00:00 By Nasdaq GlobeNewswire

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

06 Mar 2022 22:30:00 By Nasdaq GlobeNewswire

HUTCHMED announces retirement of CEO and appointment of new CEO

03 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

03 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau

01 Mar 2022 02:30:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2021 Final Results

07 Feb 2022 02:30:00 By Nasdaq GlobeNewswire